University of Edinburgh Spin-Out BIOCAPTIVA Raises £1.58M in New Funding Round

Why It Matters

The raise accelerates commercialization of a technology that could remove a key bottleneck in non‑invasive cancer diagnostics, expanding market opportunities for liquid biopsy and boosting Scotland’s biotech export profile.

Key Takeaways

• Raised £1.58M led by Archangels and new investors
• msX platform eliminates centrifugation for cfDNA extraction
• First US launch of msX kits in Boston
• New CTO brings 30 years diagnostics expertise
• Targets growing liquid biopsy market with scalable solution

Pulse Analysis

Liquid biopsy has emerged as a cornerstone of non‑invasive cancer diagnostics, yet sample preparation remains a bottleneck. Traditional workflows rely on centrifugation and multiple reagents, which can degrade cell‑free DNA and limit throughput. BIOCAPTIVA’s patented msX magnetic bead platform sidesteps these steps by extracting cfDNA directly from whole blood, delivering higher‑quality nucleic acids in a faster, automatable process. By simplifying the front‑end of the workflow, the technology promises to lower costs and expand access to precision oncology studies worldwide and patient care.

The £1.58 million round, led by Archangels with participation from Old College Capital, BBI, Scottish Enterprise and EverQuest Capital Partners, underscores confidence in the company’s commercial trajectory. The capital will fund R&D to broaden the msX product line and accelerate regulatory pathways, while also supporting the recent appointment of Alan Schafer as chief technology officer. Schafer’s three‑decade track record at Inivata, GlaxoSmithKline and other genomics firms adds deep expertise in scaling molecular diagnostics, positioning BIOCAPTIVA to navigate the competitive biotech landscape in both the UK and the United States.

If the msX kits gain traction, they could reshape how academic labs and commercial partners conduct liquid‑biopsy studies, shortening the time from sample to data. Faster, higher‑quality cfDNA extraction enables deeper genomic profiling, which may accelerate biomarker discovery and support larger clinical trials. For Scotland’s life‑science sector, BIOCAPTIVA’s export‑ready product line and job‑creating growth align with national strategies to move up the value chain, while the broader market stands to benefit from a more scalable, cost‑effective approach to non‑invasive cancer testing.

Deal Summary

BIOCAPTIVA, a University of Edinburgh spin‑out, announced it has raised £1.58 million in a new funding round led by Archangels, with participation from Old College Capital, BBI, Scottish Enterprise and EverQuest Capital Partners. The capital will support the launch of its msX liquid‑biopsy technology in the US and further R&D.